⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539783 | 0.82 | CXCR4 (0.36) | — | |
| SCHEMBL27311491 | 0.79 | — | — | |
| SCHEMBL6416529 | 0.74 | — | — | |
| SCHEMBL7349463 | 0.72 | KMT2A (0.46) | — | |
| SCHEMBL23630321 | 0.71 | — | — | |
| SCHEMBL5548332 | 0.69 | CXCR4 (0.41) | — | |
| SCHEMBL17933279 | 0.69 | — | — | |
| SCHEMBL5242501 | 0.67 | — | — | |
| SCHEMBL27724414 | 0.67 | — | — | |
| SCHEMBL10687327 | 0.66 | CD274 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738005-B2 | Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same | ZATA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190106386-A1 | AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME | NEW YORK BLOOD CENTER, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10173976-B2 | Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same | ZATA PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-1867633-A1 | Polyamine analogues as therapeutic and diagnostic agents | MediQuest Therapeutics, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7208528-B1 | Polyamine analogues as therapeutic and diagnostic agents | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7160923-B1 | Polyamine analogues as therapeutic and diagnostic agents | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1085011-A1 | Novel polyamine analogues as therapeutic and diagnostic agents | ORIDIGM CORPORATION (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6172261-B1 | BIOSYNTHESIS USING CHAIN EXTENSION | ORIDIGM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5612329-A | INTERFERENCE WITH CELL GROWTH AND PROLIFERATION | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1997-03-18 | — | — | US | disclosed |